DE69532857D1 - Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor - Google Patents

Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor

Info

Publication number
DE69532857D1
DE69532857D1 DE69532857T DE69532857T DE69532857D1 DE 69532857 D1 DE69532857 D1 DE 69532857D1 DE 69532857 T DE69532857 T DE 69532857T DE 69532857 T DE69532857 T DE 69532857T DE 69532857 D1 DE69532857 D1 DE 69532857D1
Authority
DE
Germany
Prior art keywords
respected
neurotrophic
ligand
factor
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69532857T
Other languages
English (en)
Other versions
DE69532857T2 (de
Inventor
W Caras
W Winslow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,449 external-priority patent/US6280732B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69532857D1 publication Critical patent/DE69532857D1/de
Publication of DE69532857T2 publication Critical patent/DE69532857T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69532857T 1994-10-27 1995-10-26 Neurotrophischer AL-1 Faktor, einer Ligand verwandt mit dem EPH Tyrosine Kinase Receptor Expired - Lifetime DE69532857T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33012894A 1994-10-27 1994-10-27
US330128 1994-10-27
US486449 1995-06-07
US08/486,449 US6280732B1 (en) 1994-10-27 1995-06-07 Methods of using an AL-1 neurotrophic factor immunoadhesin
PCT/US1995/014016 WO1996013518A1 (en) 1994-10-27 1995-10-26 Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor

Publications (2)

Publication Number Publication Date
DE69532857D1 true DE69532857D1 (de) 2004-05-13
DE69532857T2 DE69532857T2 (de) 2005-04-28

Family

ID=26987135

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69532857T Expired - Lifetime DE69532857T2 (de) 1994-10-27 1995-10-26 Neurotrophischer AL-1 Faktor, einer Ligand verwandt mit dem EPH Tyrosine Kinase Receptor

Country Status (7)

Country Link
EP (1) EP0787148B1 (de)
AT (1) ATE263781T1 (de)
AU (1) AU716924B2 (de)
CA (1) CA2203888C (de)
DE (1) DE69532857T2 (de)
IL (1) IL115792A (de)
WO (1) WO1996013518A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240981T3 (es) * 1994-12-06 2005-10-16 Immunex Corporation Citocina denominada lerk-7.
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
AUPP674898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
AU2001280566A1 (en) * 2000-07-14 2002-01-30 Children's Medical Center Corporation A trophic factor capable of producing a neurosalutary effect in a subject
ES2390425T3 (es) * 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
WO2003004057A1 (en) * 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
US20030152574A1 (en) * 2001-12-10 2003-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210
AU2003268345A1 (en) 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
JP2006521111A (ja) 2003-03-12 2006-09-21 バスジーン セラピューティクス， インコーポレイテッド 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004092405A2 (en) 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
ATE492564T1 (de) 2004-03-12 2011-01-15 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
WO2005090406A2 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EP1841790B1 (de) 2005-01-27 2010-11-03 The Burnham Institute Ephb-rezeptorbindende peptide
JP2009510002A (ja) 2005-09-30 2009-03-12 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 反発誘導分子（ｒｇｍ）タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
CN102083861B (zh) 2007-08-13 2016-04-13 瓦斯基因治疗公司 使用结合EphB4的人源化抗体的癌症治疗
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5951498B2 (ja) 2009-12-08 2016-07-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 網膜神経線維層変性の治療に使用するためのｒｇｍａタンパク質に対するモノクローナル抗体
NZ625403A (en) 2012-01-27 2016-03-31 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0669929T3 (da) * 1992-11-13 2007-01-29 Immunex Corp Elk-ligand, et cytokin
AU685765B2 (en) * 1992-11-13 1998-01-29 Amgen, Inc. (Eck) receptor ligands
CA2187167A1 (en) * 1994-04-04 1995-10-12 Samuel Davis Biologically active eph family ligands

Also Published As

Publication number Publication date
WO1996013518A1 (en) 1996-05-09
IL115792A0 (en) 1996-01-19
IL115792A (en) 2007-06-17
AU4405396A (en) 1996-05-23
CA2203888A1 (en) 1996-05-09
ATE263781T1 (de) 2004-04-15
CA2203888C (en) 2011-08-23
DE69532857T2 (de) 2005-04-28
EP0787148B1 (de) 2004-04-07
EP0787148A1 (de) 1997-08-06
AU716924B2 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
DE69532857D1 (de) Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor
EP2290079A3 (de) Neurotrophe Faktoren
DE69014478D1 (de) Regelungsanordnung für eine sitzheizung.
DK0397633T3 (da) Fibronectinbindende protein samt fremstilling deraf
ATE290594T1 (de) Vegf-c-rezeptorligand
DE69534778D1 (en) Cathepsin-02-protease
DE69517725D1 (de) Gerät zur Vermeidung von Flugzeugkollisionen, insbesondere mit dem Boden durch Anflugneigungskontrolle
PL321937A1 (en) Receptors of chemokines 88-2b[ckr-3] and 88c and their antibodies
DE3785885D1 (de) Zusammengesetzter draht fuer verschleissfeste ueberzuege.
DE69008098D1 (de) Verfahren und Einrichtung zur Herstellung von Federkernkonstruktionen für Matratzen, Kissen o.dgl.
DE59000024D1 (de) Verwendung von rheniumorganischen verbindungen zur oxidation von c-c-mehrfachbindungen, darauf basierende oxidationsverfahren und neue rheniumorganische verbindungen.
ATE212055T1 (de) Östrogen-rezeptor
DE3785633D1 (de) Molekuele mit bindungsstellen von antikoerpern, die katalytische eigenschaften besitzen.
DE3777421D1 (de) Hochfester stahl fuer ventilfedern, verfahren zur herstellung des stahles und daraus hergestellte ventilfedern.
WO1997021811A3 (en) Novel tyrosine kinase receptors and ligands
DE69318294D1 (de) VERBESSERTES VERFAHREN ZUR ISOLIERUNG VON SiO 2-SCHICHTEN UND PZT-, PLZT- UND PLATIN-SCHICHTEN.
DE59005310D1 (de) Mit flüssigem Brennstoff betriebenes Heizgerät.
ATE91520T1 (de) Nassgelegte bahn, verwendbar als beschichtungsunterlage.
EP0854185A3 (de) Rezeptor-Proteine zu Bestimmungszwecke und Liganden
ES2072868T3 (es) Proteina capaz de unir la fibronectina y su preparacion.
DE69634918D1 (de) Polynukleotide und polypeptide aus pathogenen mycobakterien und deren verwendung als diagnostika, impfstoffe und als ziel der chemotherapie
MX167523B (es) Catalizadores de termodesintegracion catalitica y procedimiento de termodesintegracion que utiliza tamices moleculares no zeoliticos.
DE69008535D1 (de) Humane antigammainterferonantikörper, welche detektiert und geklärt sind mit verwendung von synthetischen peptiden.
IT8620548A0 (it) Procedimento e dispositivo per la fabbricazione di prodotti in fibra di vetro, per esempio veli, feltri, filati e stoppini.
DE58902421D1 (de) Verfahren zur herstellung von ethylen/vinylacetat-copolymerisaten mit erhoehter festigkeit, neue ethylen/vinylacetat-copolymerisate und ihre verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition